Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook

Pfizer reported positive Phase 3 results for TALZENNA (talazoparib) in combination with XTANDI in HRR gene mutated metastatic castration sensitive prostate cancer. The company plans to seek expanded ...

Pfizer touts promising survival data without worsening for advanced breast cancer patients

Pfizer Inc. PFE on Tuesday announced topline results from the Phase 2 FOURLIGHT-1 study in pretreated metastatic breast ...
FierceBiotech

Pfizer's mRNA flu vaccine shows 34.5% greater efficacy than standard shot in phase 3

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...
BioPharma Dive

Pfizer aims for wider use of PARP drug in prostate cancer with new data

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer reports positive data from a Phase 2 study for the atopic dermatitis antibody

Pfizer said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive ...

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They aren't just "pandemic stocks." ...